
## Sergio RodrÃ-guez-Tajes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3922918/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rectal colonization by resistant bacteria increases the risk of infection by the colonizing strain in critically ill patients with cirrhosis. Journal of Hepatology, 2022, 76, 1079-1089.	1.8	37
2	Real-world evidence of sofosbuvir/velpatasvir as an effective and simple hepatitis C virus treatment and elimination tool in homeless populations. Future Virology, 2022, 17, 77-86.	0.9	2
3	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. Journal of Hepatology, 2022, 76, 812-821.	1.8	59
4	Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Molecular Oncology, 2022, 16, 665-682.	2.1	3
5	Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients. Journal of Hepatology, 2021, 74, 1064-1074.	1.8	52
6	Low risk of hepatitis B reactivation in patients with severe COVIDâ€19 who receive immunosuppressive therapy. Journal of Viral Hepatitis, 2021, 28, 89-94.	1.0	58
7	Efficacy of an accelerated doubleâ€dose hepatitis B vaccine regimen in patients with cirrhosis. Journal of Viral Hepatitis, 2021, 28, 1019-1024.	1.0	7
8	Oneâ€quarter of chronic hepatitis D patients reach HDVâ€RNA decline or undetectability during the natural course of the disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 462-469.	1.9	25
9	Reply to: Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question. Journal of Viral Hepatitis, 2021, 28, 1331-1332.	1.0	0
10	A novel model of care for simplified testing of HBV in African communities during the COVID-19 pandemic in Spain. Scientific Reports, 2021, 11, 17063.	1.6	11
11	Prediction of hepatocellular carcinoma after sustained virologic response in patients with compensated advanced chronic liver disease. , 2021, 59, .		0
12	Early changes in brain structure, functional connectivity and neuropsychiatric symptoms after HCV infection cure with direct-acting antivirals. European Psychiatry, 2021, 64, S254-S254.	0.1	0
13	Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. Journal of Hepatology, 2020, 72, 472-480.	1.8	130
14	Longâ€ŧerm clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia. Alimentary Pharmacology and Therapeutics, 2020, 51, 158-166.	1.9	49
15	Low seroprevalence and zero incidence rate of hepatitis E in men who have sex with men during a hepatitis A outbreak. Journal of Medical Virology, 2020, 92, 1359-1362.	2.5	6
16	Higher seroprevalence of hepatitis E virus in autoimmune hepatitis: Role of falseâ€positive antibodies. Liver International, 2020, 40, 558-564.	1.9	10
17	Improvement of sexuality after hepatitis C cure with direct acting antivirals. Liver International, 2020, 40, 2972-2977.	1.9	3
18	Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. Journal of Hepatology, 2020, 73, 1360-1367.	1.8	12

#	Article	IF	CITATIONS
19	Chronic genotype 1 hepatitis C along with cirrhosis drives a persistent imprint in virusâ€specific CD8 + T cells after directâ€acting antiviral therapies. Journal of Viral Hepatitis, 2020, 27, 1408-1418.	1.0	4
20	Longevity and replenishment of human liver-resident memory T cells and mononuclear phagocytes. Journal of Experimental Medicine, 2020, 217, .	4.2	72
21	Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. Journal of Hepatology, 2020, 73, 1415-1424.	1.8	104
22	Efficacy and safety of direct-acting antivirals in older patients with cirrhosis and high comorbidity index. European Journal of Gastroenterology and Hepatology, 2020, 32, 389-394.	0.8	1
23	Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitits after liver transplantation. GastroenterologAa Y HepatologAa (English Edition), 2020, 43, 14-21.	0.0	Ο
24	Significant decrease in the prevalence of hepatitis C infection after the introduction of direct acting antivirals. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1570-1578.	1.4	29
25	Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitits after liver transplantation. GastroenterologAa Y HepatologÃa, 2020, 43, 14-21.	0.2	2
26	Resolution of subclinical porphyria cutanea tarda after hepatitis C eradication with directâ€acting antiâ€virals. Alimentary Pharmacology and Therapeutics, 2020, 51, 968-973.	1.9	7
27	SAT-245-Prospective evaluation of the impact of hepatitis C cure on sexual dysfunction. Journal of Hepatology, 2019, 70, e740.	1.8	0
28	SAT-380-Liver-resident memory CD8 T cells do not egress into hepatic venous blood. Journal of Hepatology, 2019, 70, e802.	1.8	0
29	Simplified follow-up of patients with mild chronic hepatitis C in areas with limited access to antiviral therapy. Digestive and Liver Disease, 2019, 51, 875-881.	0.4	Ο
30	Antiâ€viral therapy can be delayed or avoided in a significant proportion of <scp>HB</scp> eAgâ€negative Caucasian patients in the Grey Zone. Alimentary Pharmacology and Therapeutics, 2018, 47, 1397-1408.	1.9	46
31	Massive hemolysis complicating acute granulomatous hepatitis. Annals of Hematology, 2018, 97, 1741-1742.	0.8	0
32	Antiviral therapy can be avoided in most HBeAg-negative Caucasian patients in the Gray Zone. Journal of Hepatology, 2018, 68, S475-S476.	1.8	0
33	Long-term immunological and clinical impact of HCV eradication with direct acting antivirals in patients with HCV-associated cryoglobulinemia vasculitis. Journal of Hepatology, 2018, 68, S528-S529.	1.8	0
34	Hepatitis A outbreak in Barcelona among men who have sex with men ( <scp>MSM</scp> ), Januaryâ€June 2017: A hospital perspective. Liver International, 2018, 38, 588-593.	1.9	36
35	Impact of hepatic encephalopathy on liver transplant waiting list mortality in regions with different transplantation rates. Clinical Transplantation, 2018, 32, e13412.	0.8	9
36	Virological and clinical characterization of a hepatitis A outbreak in Barcelona involving primarily men who have sex with men. Journal of Hepatology, 2018, 68, S182-S183.	1.8	0

#	Article	IF	CITATIONS
37	Clinical and virological predictors of response after antiviral therapy interruption in HBeAg-negative chronic hepatitits B. Journal of Hepatology, 2018, 68, S515.	1.8	Ο
38	Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure. Gastroenterology, 2018, 155, 311-315.e6.	0.6	73
39	Hepatitis B reactivation in patients with chronic hepatitis C undergoing antiâ€viral therapy with an interferonâ€free regimen. Alimentary Pharmacology and Therapeutics, 2017, 45, 1156-1161.	1.9	47
40	Treating Hepatitis C in Patients with Renal Failure. Digestive Diseases, 2017, 35, 339-346.	0.8	14
41	Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease. American Journal of Gastroenterology, 2017, 112, 1400-1409.	0.2	26
42	Excellent efficacy but increased rate of severe adverse events in HCV-infected elderly patients undergoing interferon-free therapy. Journal of Hepatology, 2017, 66, S735.	1.8	0
43	Severe Babesia microti infection in an American immunocompetent patient diagnosed in Spain. Transfusion and Apheresis Science, 2016, 55, 243-244.	0.5	9
44	Treatment of hepatitis C before and after liver transplantation. GastroenterologÃa Y HepatologÃa (English Edition), 2016, 39, 344-351.	0.0	0